Alzinova AB (publ)

ALZ.ST

Biotechnology · Healthcare

Price

kr 0.82

+0.00 (+0.00%)

Market Cap

kr 84.4M

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+469.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 17.6M (2021) → 100.5M (2025)

Winston Score History

The full picture

Alzinova is a small Swedish biotech company focused on developing treatments for Alzheimer's disease. It does not sell products yet — instead, it runs scientific research to create a drug candidate called ALZ-101, which is a vaccine designed to target toxic protein clumps in the brain that are linked to Alzheimer's. Its main "customers" are future patients with early-stage Alzheimer's, and its work is aimed at the global pharmaceutical and clinical research market.

Alzinova makes no revenue today and funds its operations through share issuances and grants, which is typical for early-stage drug developers. The company is based in Gothenburg, Sweden, and is very small, with a market cap near zero. Its potential edge lies in its patented approach to targeting a specific form of amyloid protein, but the core risk is significant: most experimental Alzheimer's drugs fail in clinical trials, and Alzinova must secure partnerships or additional funding to advance ALZ-101 through expensive later-stage testing.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+58.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

kr 0/ year

Research and development spending

Insider Activity

39.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 months

kr 13M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Alzinova AB (publ) has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-16.3%

Weak — -16.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-55.7%

Shrinking sales (-55.7% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

7/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-817.4%

Burning cash (-817.4%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial